CSNK1G2

CSNK1G2 is a serine/threonine casein kinase 1 gamma-family enzyme that operates as a signaling node in cell death, hormone-responsive transcription, and redox homeostasis (PMID:33206046, PMID:33861751, PMID:9403068). In the necroptosis pathway it acts upstream of RIPK3: auto-phosphorylation at S211/T215 in its C-terminal domain enables CSNK1G2 to bind and inhibit RIPK3 activation, and loss of CSNK1G2 in mice produces enhanced necroptosis and premature testis aging that is rescued by Ripk3 deletion or RIPK1 kinase inhibition (PMID:33206046). In ER+ breast cancer cells CSNK1G2 phosphorylates ERα at S167 to drive transcription at estrogen-responsive elements and modulate PI3K/AKT/mTOR/S6K signaling, influencing tamoxifen sensitivity in an ERα-dependent manner (PMID:33861751). Through interaction with the NADPH dual oxidase maturation factor DUOXA2 (DOXA-1 in C. elegans), CSNK1G2 promotes cellular ROS levels in a kinase-activity-dependent manner (PMID:37099597). The protein is a 416-residue kinase encoded at chromosome 19p13.3 (PMID:9403068). Beyond these roles, no unifying structural or substrate-level mechanism connecting these functions has been characterized in the available corpus.

1. 1997 Medium

   Established the basic molecular identity of human CSNK1G2 as a casein kinase 1 gamma serine/threonine kinase and placed it on the genome, providing the entry point for all later functional work.

   Evidence cDNA cloning/sequencing, FISH, and human/rodent hybrid cell panel mapping

   PMID:9403068

   Open questions at the time

   • No enzymatic substrate identified at this stage
   • SH3-motif binding to Nck was structural inference, not demonstrated binding
2. 2020 High

   Answered whether CSNK1G2 regulates programmed cell death by showing it directly binds and inhibits RIPK3, defining a kinase-dependent brake on necroptosis with an in vivo tissue phenotype.

   Evidence Co-IP/binding assays, phosphosite mutagenesis, CSNK1G2-KO mouse, epistasis with Ripk3 KO and RIPK1 inhibitor rescue

   PMID:33206046

   Open questions at the time

   • Whether CSNK1G2 phosphorylates RIPK3 directly versus inhibiting by binding alone is not resolved
   • Structural basis of S211/T215 auto-phosphorylation-driven binding unknown
3. 2021 Medium

   Connected CSNK1G2 to estrogen-responsive transcription by identifying ERα S167 as a phosphorylation target and linking the kinase to PI3K/AKT/mTOR signaling and tamoxifen response in breast cancer cells.

   Evidence shRNA knockdown, ERα S167 phosphorylation assay, ERE luciferase reporter, pathway western blots, CK1 inhibitor D4476

   PMID:33861751

   Open questions at the time

   • Direct versus indirect phosphorylation of ERα not fully separated
   • Findings from a single lab and limited cell-line panel
4. 2023 Medium

   Extended CSNK1G2 function to redox biology by showing a conserved interaction with the dual oxidase maturation factor DUOXA2/DOXA-1 that promotes ROS in a kinase-dependent manner.

   Evidence C. elegans nonallelic noncomplementation screen, Co-IP, ROS measurements in worm and human cells with CK1 inhibitor

   PMID:37099597

   Open questions at the time

   • Whether DUOXA2 is a phosphorylation substrate is not established
   • Human relevance rests on cross-species inference and single-lab validation
5. 2024 Medium

   Positioned CSNK1G2 as a downstream effector of a PKC eta cascade driving terminal CD8+ T cell exhaustion, with deletion improving T cell function and tumor control.

   Evidence Phosphoproteomic cascade mapping, CK1G2 KO, in vivo tumor and chronic infection models (preprint)

   PMID:bio_10.1101_2024.09.26.615103

   Open questions at the time

   • Direct substrates of CSNK1G2 in the exhaustion program unidentified
   • Preprint, not peer-reviewed
   • Mechanism of PKC eta-driven activation undefined

• It remains unknown what unifies CSNK1G2's roles in necroptosis, ERα signaling, ROS, and T cell exhaustion at the level of shared substrates, regulatory inputs, or structural mechanism.
• No structural model of the kinase or its substrate recognition
• Substrate set across contexts not catalogued
• Tissue-specific regulation of kinase activity uncharacterized